NOVEL PHARMA

PRESS RELEASE

Date	Title
2024.10.31	GC Pharma Announces Preclinical Findings and Ongoing Clinical Trials of Sanfilippo Syndrome Type A Drug 'GC1130A' at ADVANCE 2024
2024.08.12	GC Biopharma & Novel Pharma Receive Clinical Trial Approval from Japan's PMDA for Sanfilippo Syndrome Type A Treatment
2024.06.10	Novel Pharma's MPS IIIA Treatment 'NP3011' Receives FDA Fast Track Designation
2024.05.20	Rare Disease Specialist Novel Pharma Initiates Clinical Trials for Sanfilippo Syndrome Type A Treatment
2024.04.30	Novel Pharma Submits IND Application to MFDS for Clinical Trial of Sanfilippo Syndrome Treatment
2024.04.23	Novel Pharma Submits IND Application to U.S. FDA for Sanfilippo Syndrome Treatment
2024.04.12	Novel Pharma's Research on MPS IIIA Therapy Selected as Best Poster at International Mucopolysaccharidosis Symposium
2024.02.13	Novel Pharma Announces Non-clinical Results for Sanfilippo Syndrome Treatment at World Symposium
2024.01.19	Novel Pharma Receives EMA Orphan Drug Designation for Treatment of MPSIIIA
2023.11.13	Novel Pharma Announces Non-Clinical Results of MPS IIIA Treatment at Ajou University Hospital Symposium